2021 Annual Conference   |  March 31 - April 2, 2021  |  Online

Looking for the 2022 Annual Conference?  Click here!

2021 Cholangiocarcinoma Foundation Annual Conference

The 2021 Conference will build upon the foundation laid at previous year's meetings as key opinion leaders both nationally and internationally, come together to collaborate and exchange knowledge. The program will seek to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma by:


Increasing the knowledge and understanding of attendees about key issues central to the prevention, diagnosis, treatment, and cure for cholangiocarcinoma

A New Perspective

Identifying gaps and gathering consensus on rapidly changing advances in basic, translational, and clinical research


Stimulating interdisciplinary cross-cooperation and sharing best practices by developing, strengthening, and supporting collaborations


Fostering dialogue and inspiring innovation across the world

Further, because patients living with cholangiocarcinoma have a direct stake in their own medical care and are in a unique position to provide input, CCF has expanded its Annual Conference to include programming that addresses questions and concerns that are important to patients and their families. Patients and caregivers-having experienced the disease firsthand-will be invited to learn about cholangiocarcinoma, share their personal experiences, and contribute to future efforts to further cholangiocarcinoma research.

Meet our 2021 Annual Conference Co-Chairs


John Bridgewater, MD, PhD

UCL Cancer Institute

London, UK


Funda Meric-Bernstam, MD

MD Anderson Cancer Center

Houston, TX

2020 Conference by the Numbers

  • 800+ Patients & Caregivers
  • 300+ Clinicians & Researchers
  • 400+ Industry Representatives & Sponsors
  • 44 Countries Represented
  • 49 States, DC & Puerto Rico

Who Should Attend?

Who Should Attend?

  • Researchers
  • Physicians
  • Oncologists
  • Radiologists
  • Surgeons

  • Gastroenterologists
  • Hepatologists
  • Nurses specializing in oncology, intensive care, and palliative care
  • Pharmaceutical Companies

  • Government Regulators
  • Policymakers
  • Patients, Caregivers and others invested in the field of cholangiocarcinoma